esmo congress, copenhagen 2016 non abstract related … · title presentation 2 tumour evolution...
TRANSCRIPT
1
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Keynote presentations .................................................................................................................................... 2
Basic science and translational research ........................................................................................................ 3
Breast cancer, early stage .............................................................................................................................. 6
Breast cancer, metastatic ............................................................................................................................... 8
CNS tumours ............................................................................................................................................... 10
Developmental therapeutics ......................................................................................................................... 12
Gastrointestinal tumours, colorectal ............................................................................................................ 14
Gastrointestinal tumours, non-colorectal ..................................................................................................... 16
Genitourinary tumours, prostate .................................................................................................................. 18
Genitourinary tumours, non prostate ........................................................................................................... 20
Gynaecological cancers ............................................................................................................................... 22
Haematological Malignancies ..................................................................................................................... 24
Head & neck cancer ..................................................................................................................................... 26
Immunotherapy of cancer ............................................................................................................................ 28
Melanoma and other skin tumours .............................................................................................................. 30
NETs and endocrine tumours ...................................................................................................................... 32
Non-metastatic NSCLC and other thoracic malignancies ........................................................................... 34
NSCLC, metastatic ...................................................................................................................................... 36
Public health and health economics ............................................................................................................. 39
Sarcoma ....................................................................................................................................................... 41
Supportive and palliative care ..................................................................................................................... 43
Congress Highlights..................................................................................................................................... 46
ESMO YO sessions ..................................................................................................................................... 47
Special Session ............................................................................................................................................ 51
Special Session ............................................................................................................................................ 52
Special Session ............................................................................................................................................ 53
Special Session ............................................................................................................................................ 54
Special Session ............................................................................................................................................ 55
Special Session ............................................................................................................................................ 56
Special Session ............................................................................................................................................ 57
Special Session ............................................................................................................................................ 58
2
ESMO Congress, Copenhagen 2016
NON ABSTRACT RELATED PROGRAMME Keynote presentations
Saturday, 8 October 2016 – 13:00-13:45 45 mins
Topic Immunotherapy: From the basic to the clinic
Title The development of checkpoint inhibitors
Chair Rolf A. Stahel, CH
Speaker James P. Allison, US
Sunday, 9 October 2016 – 13:00-13:45 45 mins
Title The art of the possible: Bridging the gap between genomics and patient care?
Chair Richard Marais, UK
Speaker Emile Voest, NL
Monday, 10 October 2016 – 13:00-13:45 45 mins
Title The patient journey: Is cancer cure around the corner?
Chair Fortunato Ciardiello, IT
Speaker Jean-Charles Soria, FR
3
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME Basic science and translational research
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Primary and secondary resistance to targeted therapy and immunotherapy
Speaker Jeffrey Engelman, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium 1 Friday, 7 October 2016 – 16:00-17:30 90 mins
Title symposium Adapting clinical trials to tumour biology: Shooting at a moving target
Chair Alberto Bardelli, IT
Co-Chair TBC
Title presentation 1 Introduction
Speaker 1 TBC
Lecture time 1 5’
Title presentation 2 What have we learned from failures?
Speaker 2 Emma Dean, UK
Lecture/disc time 2 20’
Title presentation 3 Master protocols and basket trials: Have we found the answer?
Speaker 3 Keith Flaherty, US
Lecture/disc time 3 20’
Title presentation 4 Modulating responses using CtDNA
Speaker 4 Alberto Bardelli, IT
Lecture/disc time 4 20’
Title presentation 5 New clinical trial design
Speaker 5 Susan Galbraith, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Alberto Bardelli, IT
Lecture/disc time 6 5’
4
Special Symposium 2 Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Using biomarkers to monitor the dynamics of tumour responses to therapy
Chair Joan Seoane, ES
Co-Chair Alberto Sobrero, IT
Title presentation 1 Introduction
Speaker 1 Alberto Sobrero, IT
Lecture time 1 5’
Title presentation 2 Biomarkers of the host
Speaker 2 George Coukos, CH
Lecture/disc time 2 20’
Title presentation 3 Circulating biomarkers to monitor patient responses
Speaker 3 Caroline Dive, UK
Lecture/disc time 3 20’
Title presentation 4 Patient derived models to select treatment
Speaker 4 Joan Seoane, ES
Lecture/disc time 4 20’
Title presentation 5 Using dynamic changes in inflammation to monitor tumour responses
Speaker 5 Paul Tumeh, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Joan Seoane, ES
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Targeting the genes is not enough: The patients and tumour behaviour also matter
Chair Pasi Jånne, US
Title presentation 1 One mutation, many cancers
Speaker 1 David Huntsman, CA
Title presentation 2 Resistance mutations and cell context specific adaptive responses
Speaker 2 Pasi Jånne, US
Title presentation 3 Considering clonal evolution in breast cancer management
Speaker 3 Carlos Caldas, UK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
5
Special session Saturday, 8 October 2016 – 09:15-10:45 90 mins
Title symposium Will we ever conquer resistance?
Chair Daniel Peeper, NL
Co-Chair Joan Seoane, ES
Title presentation 1 Introduction
Speaker 1 Daniel Peeper, NL
Lecture time 1 5’
Title presentation 2 Tumour evolution under the selective pressure of treatment
Speaker 2 Charles Swanton, UK
Lecture/disc time 2 20’
Title presentation 3 Mechanisms of resistance mediated by the tumour stroma
Speaker 3 Erik Sahai, UK
Lecture/disc time 3 20’
Title presentation 4 New approaches to BRAF resistant disease
Speaker 4 Richard Marais, UK
Lecture/disc time 4 20’
Title presentation 5 What can we learn from single patients?
Speaker 5 Daniel Peeper, NL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Joan Seoane, ES
Lecture/disc time 6 5’
6
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Breast cancer, early stage
Educational session Saturday, 8 October 2016 – 09:00-10:30 90 mins
Topic The neoadjuvant approach in the multidisciplinary setting
Chair Sibylle Loibl, DE
Co-Chair Marco Colleoni, IT
Title presentation 1 Systemic neoadjuvant treatment
Speaker 1 Sibylle Loibl, DE
Lecture/disc time 30’
Title presentation 2 Surgical challenges after neoadjuvant therapy
Speaker 2 Isabel Rubio, ES
Lecture/disc time 30’
Title presentation 3 The impact of tumour stage and response on radiotherapy indications
Speaker 3 Jacques Bernier, CH
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title What is the clinical utility of gene expression-based tests in early breast cancer?
Speaker Aleix Prat, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 11:00-12:30 90 mins
Title symposium Treatment options in patients with early breast cancer and BRCA mutation or family history of cancer
Chair Hervé Bonnefoi, FR
Co-Chair Andrew Tutt, UK
Title presentation 1 Introduction
Speaker 1 Hervé Bonnefoi, FR
Lecture time 1 5’
Title presentation 2 Surgical options
Speaker 2 Marian Menke-Pluymers, NL
Lecture/disc time 2 20’
Title presentation 3 Systemic therapy
Speaker 3 Andrew Tutt, UK
Lecture/disc time 3 20’
Title presentation 4 Patient's preference
Speaker 4 Karen Benn, IT
Lecture/disc time 4 20’
Title presentation 5 Fertility issues
Speaker 5 Hatem A. Azim, Jr., BE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Andrew Tutt, UK
Lecture/disc time 6 5’
7
Multidisciplinary patient cases Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Treatment approaches in elderly patients
Chair Silvio Monfardini, IT
Title presentation 1 Case presentation
Speaker 1 Silvio Monfardini, IT
Title presentation 2 Bringing geriatrics into oncology
Speaker 2 Silvio Monfardini, IT
Title presentation 3 Tailoring local treatment to the elderly
Speaker 3 Ian Kunkler, UK
Title presentation 4 Optimising systemic therapy
Speaker 4 Hans Wildiers, BE
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
8
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Breast cancer, metastatic
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic New developments in the management of ER-positive metastatic breast cancer
Chair Giuseppe Curigliano, IT
Co-Chair Robert Coleman, UK
Title presentation 1 Unlocking the pathways of endocrine resistance
Speaker 1 Giuseppe Curigliano, IT
Lecture/disc time 30’
Title presentation 2 Current and emerging treatment approaches: An embarrassment of riches?
Speaker 2 Nadia Harbeck, DE
Lecture/disc time 30’
Title presentation 3 Minimising the toxicities of targeted therapies
Speaker 3 Thomas Bachelot, FR
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 – 16:30-18:00 90 mins
Topic HER2+ advanced breast cancer: A few more questions and many more answers
Chair Javier Cortes, ES
Co-Chair Fatima Cardoso, PT
Title presentation 1 Individualising first line treatment options for HER2+ metastatic breast cancer
Speaker 1 Heikki Joensuu, FI
Lecture/disc time 30’
Title presentation 2 Second line, salvage and emerging treatments for HER2+ disease
Speaker 2 Javier Cortes, ES
Lecture/disc time 30’
Title presentation 3 The role of the immune response in HER2+ disease: Is it relevant for patient care?
Speaker 3 Sherene Loi, AU
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic How to translate evidence based guidelines into everyday treatment
Final Title Are guidelines necessary for everyday treatment in metastatic breast cancer?
Speaker Fatima Cardoso, PT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
9
Special symposium Sunday, 9 October 2016 – 14:45-16:15 90 mins
Title symposium Triple negative breast cancer: Do we now have something to be positive about?
Chair Elzbieta Senkus, PL
Co-Chair Andrew Tutt, UK
Title presentation 1 Introduction: The current landscape
Speaker 1 Elzbieta Senkus, PL
Lecture time 1 5’
Title presentation 2 Molecular “dissection” of TNBC to identify therapeutic targets
Speaker 2 Fabrice André, FR
Lecture/disc time 2 20’
Title presentation 3 Targeting DNA repair mechanisms
Speaker 3 Rebecca Dent, SG
Lecture/disc time 3 20’
Title presentation 4 Androgen receptor blockade
Speaker 4 Hervé Bonnefoi, FR
Lecture/disc time 4 20’
Title presentation 5 Immunotherapeutic approaches
Speaker 5 Peter Schmid, UK
Lecture/disc time 5 20’
Title presentation 6 Concluding discussion
Speaker 6 Led by Co-Chair
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 - 15:00-16:00 60 mins
Topic Special situations in advanced breast cancer: De novo and limited metastatic disease
Chair Pier Franco Conte, IT
Title presentation 1 Management of brain metastases in breast cancer 1 case
Speaker 1 Nancy Lin, US
Title presentation 2 Case presentation
Speaker 2 Pier Franco Conte, IT
Title presentation 2 Local therapy approaches
Speaker 2 Ian Kunkler, UK
Title presentation 3 Systemic therapy approaches
Speaker 3 Pier Franco Conte, IT
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
10
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
CNS tumours
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Wind of change: Challenges in neuro-oncology in 2016
Chair Alba Brandes, IT
Co-Chair Michael Brada, UK
Title presentation 1 The new WHO classification: Is molecular diagnosis ready for prime time?
Speaker 1 Pieter Wesseling, NL
Lecture/disc time 30’
Title presentation 2 Newly diagnosed and recurrent glioblastoma: Where are we going?
Speaker 2 Alba Brandes, IT
Lecture/disc time 30’
Title presentation 3 Standard and future approaches in the treatment of rare CNS tumours
Speaker 3 Michael Brada, UK
Lecture/disc time 30’
Educational session 2 Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Brain metastases: Are we ready for a paradigm shift?
Chair Roger Stupp, CH
Co-Chair Enrico Franceschi, IT
Title presentation 1 The biology of brain metastases: What should we know?
Speaker 1 Manuel Valiente, ES
Lecture/disc time 30’
Title presentation 2 Is the blood brain barrier still a limit for targeted therapies in brain metastases?
Speaker 2 Matthias Preusser, AT
Lecture/disc time 30’
Title presentation 3 The treatment of brain metastases in the era of immuno-oncology
Speaker 3 Roger Stupp, CH
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final title The revolution of molecular diagnosis in anaplastic gliomas
Speaker Wolfgang Wick, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
11
Special symposium Sunday, 9 October 2016 – 11:00-12:30 90 mins
Title symposium Moving steps forward: What’s new in the treatment of brain tumours
Chair Patrick Wen, US
Co-Chair Alba Brandes, IT
Title presentation 1 Introduction
Speaker 1 Alba Brandes, IT
Lecture time 1 5’
Title presentation 2 Immunotherapy for glioblastoma: Quo vadis?
Speaker 2 Michael Weller, CH
Lecture/disc time 2 20’
Title presentation 3 Identifying and overcoming challenges in immunotherapy for brain tumours: The iRANO approach
Speaker 3 Patrick Wen, US
Lecture/disc time 3 20’
Title presentation 4 Targeting angiogenesis in high-grade gliomas: The long and winding road
Speaker 4 Evanthia Galanis, US
Lecture/disc time 4 20’
Title presentation 5 How can we deal with the toxicity of new agents?
Speaker 5 Deborah Blumenthal, IL
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Patrick Wen, US
Lecture/disc time 6 5’
Multidisciplinary patient cases Saturday, 8 October 2016 – 11:00-12:00 60 mins
Topic Low grade glioma: Back to the future
Chair Martin J. van den Bent, NL
Title presentation 1 Case presentation
Speaker 1 Martin J. van den Bent, NL
Title presentation 2 The role of surgery in low grade gliomas: Do timing and extent of resection matter?
Speaker 2 Hugues Duffau, FR
Title presentation 3 When and how treat low grade gliomas
Speaker 3 Martin J. van den Bent, NL
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 35’ Discussion
12
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Developmental therapeutics
Educational session Sunday, 9 October 2016 – 09:00-10:30 90 mins
Topic Upgrading your knowledge on how drug development works nowadays
Chair Udai Banerji, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Defining the right dose: When and how
Speaker 1 Jan Schellens, NL
Lecture/disc time 30’
Title presentation 2 To test or not to test: The role of biomarkers in assisting drug development
Speaker 2 Udai Banerji, UK
Lecture/disc time 30’
Title presentation 3 New side effects of novel drugs that you should be aware of
Speaker 3 David Tan, SG
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 09:30-10:30 60 mins
Final Title Genetic essentials for the modern practicing oncologist
Speaker Emile Voest, NL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Monday, 10 October 2016 - 14:45-16:15 90 mins
Title symposium Drugs you will be using in 2020
Chair Jordi Rodon, ES
Co-Chair Philippe Aftimos, BE
Title presentation 1 Introduction
Speaker 1 Philippe Aftimos, BE
Lecture time 1 5’
Title presentation 2 Antibody-drug conjugates: Drones targeting tumours?
Speaker 2 Bernard Fine, US
Lecture/disc time 2 15’
Title presentation 3 Engineered peptide therapeutics and other protein therapies (bispecific, BITE´s, DARPins…).
Speaker 3 Michael T. Stumpp, CH
Lecture/disc time 3 15’
Title presentation 4 Crafting selective and artisan kinase inhibitors
Speaker 4 Brian Hodous, US
Lecture/disc time 4 15’
Title presentation 5 Using viruses and bacteria to treat cancer
Speaker 5 Ramon Alemany, ES
Lecture/disc time 5 15’
Title presentation 6 Genes to treat a genetic disease such as cancer: RNA therapeutics
Speaker 6 Pierfrancesco Tassone, IT
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Jordi Rodon, ES
Lecture/disc time 7 10’
13
Multidisciplinary patient cases Saturday, 8 October 2016 – 15:00-16:00 60 mins
Topic Precision medicine in the clinic: How do I provide it?
Chair Charles Ferté, FR
Title presentation 1 Patient case presentation
Speaker 1 Philippe Aftimos, BE
Title presentation 2 From raw data to a comprehensive genetic report
Speaker 2 Ana Vivancos, ES
Title presentation 3 From an NGS test to a clinical decision
Speaker 3 Charles Ferté, FR
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 35’ Discussion
14
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Gastrointestinal tumours, colorectal
Educational session 1
Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Metastatic colorectal cancer: Providing the continuum of care
Chair Christophe Tournigand, FR
Co-Chair Camilla Qvortrup, DK
Title presentation 1 What can be done beyond first line targeted agents: Switch or continue?
Speaker 1 Dirk Arnold, DE
Lecture/disc time 30’
Title presentation 2 Re-introduction: Is it a valid concept?
Speaker 2 Christophe Tournigand, FR
Lecture/disc time 30’
Title presentation 3 On-treatment biomarkers: Do they help to define the best sequence?
Speaker 3 Clara Montagut, ES
Lecture/disc time 30’
Educational session 2
Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Hot topics in the adjuvant treatment of colorectal cancer
Chair Julien Taieb, FR
Co-Chair Richard Adams, UK
Title presentation 1 BRAF, KRAS, MSI and gene signatures: Where are we now?
Speaker 1 Ramon Salazar, ES
Lecture/disc time 30’
Title presentation 2 How best to treat adjuvant rectal cancer
Speaker 2 Richard Adams, UK
Lecture/disc time 30’
Title presentation 3 Complex colon cancer patients in the adjuvant setting (to include elderly, stage II, comorbidities)
Speaker 3 Thierry André, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title Synchronous metastatic colorectal cancer: Addressing difficult situations
Speaker Gunnar Folprecht, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
15
Special symposium Sunday, 9 October 2016 – 09:00-10:30 90 mins
Title symposium New molecular challenges in CRC
Chair Sabine Tejpar, BE
Co-Chair Per Pfeiffer, DK
Title presentation 1 Introduction
Speaker 1 Per Pfeiffer, DK
Lecture time 1 5’
Title presentation 2 New classification of CRC: “Gone molecular”?
Speaker 2 Daniela Aust, DE
Lecture/disc time 2 15’
Title presentation 3 Liquid biopsies: Ever closer to daily practice?
Speaker 3 Pierre Laurent-Puig, FR
Lecture/disc time 3 15’
Title presentation 4 BRAF mutations: What are the treatment options?
Speaker 4 Fotios Loupakis, IT
Lecture/disc time 4 15’
Title presentation 5 Patients with rare molecular alterations: Do they need a precision approach?
Speaker 5 Salvatore Siena, IT
Lecture/disc time 5 15’
Title presentation 6 Immunotherapy in mCRC: MSI and beyond
Speaker 6 Neil Segal, US
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Sabine Tejpar, BE
Lecture/disc time 7 10’
Multidisciplinary patient cases Monday, 10 October 2016 – 11:00-12:00 60 mins
Topic Liver dominant disease
Chair Thomas Gruenberger, AT
Title presentation 1 Is the potential of cure adequately depicted within tumour boards? (how to best evaluate the potentially resectable patients in this population)
Speaker 1 Thomas Gruenberger, AT
Title presentation 2 What is the best induction, and which post-op therapies should be used? (how to go to surgery with the best medical treatment and if no surgery is performed do we have a standard?)
Speaker 2 Claus-Henning Köhne, DE
Title presentation 3 Radiofrequency and intra-arterial treatments: How to place them (IAT and RFA for selected patients or for everybody?)
Speaker 3 Thierry de Baere, FR
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
16
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME Gastrointestinal tumours, non-colorectal
Educational session 1 Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic What is new in liver cancer?
Chair Josep Llovet, ES
Co-Chair Michel Ducreux, FR
Title presentation 1 The biology of liver cancer
Speaker 1 Jessica Zucman-Rossi, FR
Lecture/disc time 30’
Title presentation 2 Stage-dependent management of HCC and news in systemic treatment
Speaker 2 Josep Llovet, ES
Lecture/disc time 30’
Title presentation 3 New developments in locoregional treatment
Speaker 3 Jens Ricke, DE
Lecture/disc time 30’
Educational session 2 Saturday, 8 October 2016 – 16:30-18:00 90 mins
Title symposium Advances in precision medicine of gastric cancer
Chair Yoon-Koo Kang, KR
Co-Chair Yelena Janjigiian, US
Title presentation 1 Genetic and immune signatures of gastric cancer to inform prognosis and clinical decision making
Speaker 1 Axel Hillmer, SG
Lecture/disc time 1 25’
Title presentation 2 Surgical precision: Novel techniques and perspectives
Speaker 2 Christophe Mariette, FR
Lecture/disc time 2 25’
Title presentation 3 Novel drugs: More precise, more efficacious and safer?
Speaker 3 Yelena Janjigian, US
Lecture/disc time 3 25’
Title presentation 4 Conclusions and clinical perspectives
Speaker 4 Yoon-Koo Kang, KR
Lecture/disc time 4 15’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title Challenges in pancreatic cancer
Speaker Manuel Hidalgo, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
17
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Topic Genetics and epigenetics of gastric cancer: What clinicians should know
Chair Fatima Carneiro, PT
Co-Chair Axel Hillmer, SG
Title presentation 1 Introduction
Speaker 1 Axel Hillmer, SG
Lecture time 5’
Title presentation 2 How to detect and manage familial and hereditary gastric cancer
Speaker 2 Fatima Carneiro, PT
Lecture time 20’
Title presentation 3 Genetics of gastric cancer: Clinical implications
Speaker 3 Ian Chau, UK
Lecture time 20’
Title presentation 4 DNA methylation and epigenetic changes in gastric cancer: From bench to bedside
Speaker 4 Toshikazu Ushijima, JP
Lecture time 20’
Title presentation 5 As a clinician, what do I make of this information?
Speaker 5 Per Pfeiffer, DK
Lecture time 20’
Title presentation 6 Conclusion
Speaker 6 Fatima Carneiro, PT
Lecture time 5’
Multidisciplinary patient cases Sunday, 9 October 2016 – 15:00-16:00 60 mins
Topic Biliary tract cancer: Klatskin tumour
Chair Michel Ducreux, FR
Title presentation 1 Case presentation
Speaker 1 Michel Ducreux, FR
Title presentation 2 Role of surgery and transplantation
Speaker 2 René Adam, FR
Title presentation 3 Medical treatment
Speaker 3 Michel Ducreux, FR
Title presentation 4 Radiation
Speaker 4 Christopher Crane, US
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
18
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Genitourinary tumours, prostate
Educational session 1 Friday, 7 October 2016 – 14:00-15:30 90 mins
Topic Imaging in metastatic prostate cancer
Chair Frederic Lecouvet, BE
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 The role of whole body MRI
Speaker 1 Frederic Lecouvet, BE
Lecture/disc time 1 30’
Title presentation 2 The role of PET/CT
Speaker 2 Uwe Haberkorn, DE
Lecture/disc time 2 30’
Title presentation 3 Radiographic progression free survival: A new biomarker of response to treatment?
Speaker 3 Michael Morris, US
Lecture/disc time 3 30’
Educational session 2 Sunday, 9 October 2016 – 11:00-12:30 90 mins
Topic Multimodality treatment for hormone-naïve metastatic prostate cancer
Chair TBC – one of the speakers
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Docetaxel for prostate cancer: Best timing and right patient
Speaker 1 Nick James, UK
Lecture/disc time 1 30’
Title presentation 2 Radiation to the primary tumour in metastatic disease: When and whom
Speaker 2 Alberto Bossi, FR
Lecture/disc time 2 30’
Title presentation 3 Does radical prostatectomy have an impact on long-term outcomes of patients with metastatic prostate cancer?
Speaker 3 Axel Heidenreich, DE
Lecture/disc time 3 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Minimising the complications of ADT and bone disease in prostate cancer
Speaker Matthew Smith, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
19
Special symposium Monday, 10 October 2016 – 09:00-10:30 90 mins
Title symposium Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Chair David Olmos, ES
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Chair or Co-Chair
Lecture time 1 5’
Title presentation 2 Translating the genomics landscape into clinical practice
Speaker 2 Rob Bristow, CA
Lecture/disc time 2 20’
Title presentation 3 What is the role of CTCs?
Speaker 3 Howard Scher, US
Lecture/disc time 3 20’
Title presentation 4 Using circulating tumour DNA studies to improve the management of prostate cancer patients
Speaker 4 Gert Attard, UK
Lecture/disc time 4 20’
Title presentation 5 Molecularly defining neuroendocrine prostate cancer
Speaker 5 Himisha Beltran, US
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Chair or Co-Chair
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 15:00-16:00 60 mins
Topic Oligometastatic disease in prostate cancer patients
Chair Ronald de Wit, NL
Title presentation 1 Radiation with curative intent
Speaker 1 Piet Ost, BE
Title presentation 2 Radical surgical intervention
Speaker 2 Steven Joniau, BE
Title presentation 3 Systemic treatments
Speaker 3 Ronald de Wit, NL
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
20
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Genitourinary tumours, non prostate
Educational session Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic Emerging concepts in daily management of urothelial tumours
Chair Aris Bamias, GR
Co-Chair Vincent Khoo, UK
Title presentation 1 How to select systemic therapy in bladder cancer
Speaker 1 Aris Bamias, GR
Lecture/disc time 30’
Title presentation 2 How to interpret genomic reports in the management of urothelial malignancies (focus on bladder)
Speaker 2 Jim Catto, UK
Lecture/disc time 30’
Title presentation 3 Targeted therapies in urothelial malignancies (including cisplatin and new targets)
Speaker 3 Jonathan E. Rosenberg, US
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Topic Difficult to treat potentially curable patient
Final Title Topic: Management of poor risk germ cell tumours
Speaker Christian Kollmannsberger, CA
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Immunotherapy in GU malignancies
Chair Joaquim Bellmunt, US
Co-Chair Manuela Schmidinger, AT
Title presentation 1 Introduction
Speaker 1 Joaquim Bellmunt, US
Lecture time 1 5’
Title presentation 2 Biology and new immunological targets in GU malignancies
Speaker 2 John Haanen, NL
Lecture/disc time 2 20’
Title presentation 3 Biomarkers of response and progression in (GU) immunotherapy
Speaker 3 Toni Choueiri, US
Lecture/disc time 3 20’
Title presentation 4 Immunotherapy in urothelial cancers
Speaker 4 Joaquim Bellmunt, US
Lecture/disc time 4 20’
Title presentation 5 Immunotherapy in kidney cancer
Speaker 5 Laurence Albiges, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Manuela Schmidinger, AT
Lecture/disc time 6 5’
21
Multidisciplinary patient cases Saturday, 8 October 2016 – 11:00-12:00 60 mins
Topic Complex symptomatic RCC with bone metastasis
Chair Viktor Grünwald, DE
Title presentation 1 Case presentation
Speaker 1 Viktor Grünwald, DE
Title presentation 2 Every patient with bone metastases should be evaluated for surgical intervention
Speaker 2 Axel Bex, NL
Title presentation 3 Local therapy should implement radiotherapy in bone disease
Speaker 3 Vincent Khoo, UK
Title presentation 4 When medical treatment is just enough in bone disease
Speaker 4 Viktor Grünwald, DE
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
22
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Gynaecological cancers
Educational session 1 Saturday, 8 October 2016 – 14:45-16:15 90 mins
Topic Difficult decisions in gynaecological oncology
Chair Isabelle Ray-Coquard, FR
Co-Chair Andres Poveda, ES
Title presentation 1 Adjuvant therapy of endometrial cancer
Speaker 1 Carien Creutzberg, NL
Lecture/disc time 30’
Title presentation 2 Management of vulnerable patients with gynaecological cancers
Speaker 2 Gilles Freyer, FR
Lecture/disc time 30’
Title presentation 3 Rare ovarian tumours: A special focus on sex cord and germ cell tumours
Speaker 3 Isabelle Ray-Coquard, FR
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 – 09:00-10:30 90 mins
Topic Advances in targeted therapy in gynaecological cancers
Chair Jonathan Ledermann, UK
Co-Chair Mansoor Mirza, DK
Title presentation 1 Positioning anti-angiogenic therapy in the ovarian cancer treatment pathway
Speaker 1 Philipp Harter, DE
Lecture/disc time 30’
Title presentation 2 PARP inhibitors in ovarian cancer: What are the next steps?
Speaker 2 Jonathan Ledermann, UK
Lecture/disc time 30’
Title presentation 3 Cervical cancer therapy in 2016
Speaker 3 Mansoor Mirza, DK
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 09:30-10:30 60 mins
Session title Genetic counselling
Final Title BRCA testing in ovarian cancer: Who, why, when and how
Presentation 1 BRCA testing to drive therapy in ovarian cancer
Speaker 1 Eric Pujade-Lauraine, FR
Presentation 2 BRCA testing and prevention in ovarian cancer
Speaker 2 Judith Balmaña, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
23
Special symposium Sunday, 9 October 2016 – 14:45-16:15 90 mins
Title symposium Personalised medicine in gynaecological cancers
Chair Andres Poveda, ES
Co-Chair Charlie Gourley, UK
Title presentation 1 Introduction
Speaker 1 Andres Poveda, ES
Lecture time 1 5’
Title presentation 2 Immunotherapy in ovarian cancer
Speaker 2 Lana Kandalaft, CH
Lecture/disc time 2 20’
Title presentation 3 Genomic profiling of endometrial cancer
Speaker 3 Xavier Matias-Guiu, ES
Lecture/disc time 3 20’
Title presentation 4 Genomic profiling of ovarian cancer
Speaker 4 Charlie Gourley, UK
Lecture/disc time 4 20’
Title presentation 5 How to test and define HRD positive population in ovarian cancer
Speaker 5 Iain McNeish, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Charlie Gourley, UK
Lecture/disc time 6 5’
Multidisciplinary patient cases Monday, 10 October 2016 – 11:00-12:00 60 mins
Topic Current options for recurrent platinum sensitive ovarian cancer
Chair Antonio González-Martín, ES
Title presentation 1 Case presentation
Speaker 1 Antonio González-Martín, ES
Title presentation 2 Surgery is an option in platinum sensitive recurrence
Speaker 2 Christian Marth, AT
Title presentation 3 How imaging can help select patients for optimal surgery
Speaker 3 Vincent Vandecaveye, BE
Title presentation 4 Sensitive pop and systemic treatment: Which option for which patient?
Speaker 4 Antonio González-Martín, ES
Lecture/disc time Each speaker c. 10’ plus intro 5’ and 25’ Discussion
24
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Haematological Malignancies
Educational session Monday, 10 October 2016 – 09:15-10:45 90 mins
Topic Rare lymphomas: Recent developments in diagnostic and treatment
Chair Catherine Thieblemont, FR
Co-Chair Armando López-Guillermo, ES
Title presentation 1 Enteropathy associated lymphoma
Speaker 1 Otto Visser, NL
Lecture/disc time 30’
Title presentation 2 Marginal zone lymphoma
Speaker 2 Catherine Thieblemont, FR
Lecture/disc time 30’
Title presentation 3 Waldenström's macroglobulinemia
Speaker 3 Meletios A Dimopoulos, GR
Lecture/disc time 30’
Challenge your Expert Sunday, 8 October 2016 – 08:00-09:00 60 mins
Topic Diagnosis and treatment of myeloma
Final Title Novel criteria for diagnosing multiple myeloma and their therapeutic implications
Speaker Jesus San Miguel, ES
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium Emerging therapeutic strategies in lymphoma
Chair Peter Johnson, UK
Co-Chair Andrés J. M. Ferreri, IT
Title presentation 1 Introduction
Speaker 1 Andrés J. M. Ferreri, IT
Lecture time 1 5’
Title presentation 2 Hodgkin’s Lymphoma: How to incorporate novel agents into standard care of treatment
Speaker 2 Peter Johnson, UK
Lecture/disc time 2 20’
Title presentation 3 CLL: Moving towards chemotherapy and free approaches
Speaker 3 Paolo Ghia, IT
Lecture/disc time 3 20’
Title presentation 4 Mantle cell lymphoma: Impact of novel agents on treatment algorithms
Speaker 4 Simon Rule, UK
Lecture/disc time 4 20’
Title presentation 5 Follicular lymphoma: Novel developments beyond chemotherapy
Speaker 5 Eva Kimby, SE
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Peter Johnson, UK
Lecture/disc time 6 5’
25
Multidisciplinary patient cases Sunday, 9 October 2016 – 09:30-10:30 60 mins
Topic CNS Lymphoma
Chair Francesc Graus, ES
Title presentation 1 Primary CNS lymphoma
Speaker 1 Francesc Graus, ES
Title presentation 2 Secondary CNS lymphoma
Speaker 2 Andrés J. M. Ferreri, IT
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 40’ Discussion
26
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Head & neck cancer
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Induction chemotherapy: Is there any new data to revisit an inconclusive approach?
Chair Marco Merlano, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 New data from meta-analysis
Speaker 1 Wilfried Budach, DE
Lecture/disc time 30’
Title presentation 2 Emerging clinical trial data
Speaker 2 Marco Merlano, IT
Lecture/disc time 30’
Title presentation 3 Induction chemotherapy: Is there any new data from randomized trials to revisit an inconclusive approach?
Speaker 3 Jean Bourhis, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic Rare tumours in HNC: A practical approach
Final Title Management of sinonasal tumours
Speaker Paolo Bossi, IT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 09:00-10:30 90 mins
Title symposium Translating tumour biology into novel therapeutic approaches in HNSCC
Chair Robert L. Ferris, US
Co-Chair Amanda Psyrri, GR
Title presentation 1 Introduction
Speaker 1 Amanda Psyrri, GR
Lecture time 1 5’
Title presentation 2 Targeting tumour hypoxia
Speaker 2 Vincent Grégoire, BE
Lecture/disc time 2 20’
Title presentation 3 Comparison of the genetic landscape of HPV+ and HPV- head and neck cancers
Speaker 3 Paul Brennan, UK
Lecture/disc time 3 20’
Title presentation 4 The role of immunotherapy in HNSCC
Speaker 4 Robert L. Ferris, US
Lecture/disc time 4 20’
Title presentation 5 Novel therapeutic strategies in EBV associated NPC
Speaker 5 Anthony Chan, HK, CN
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Robert L. Ferris, US
Lecture/disc time 6 5’
27
Multidisciplinary patient cases Monday, 10 October 2016 – 16:30-17:30 60 mins
Topic Challenges in the management of HPV- associated OPC
Chair Danny Rischin, AU
Title presentation 1 Early stage HPV positive OPC patient (minimally invasive surgery vs Radiotherapy)
Speaker 1 Christian Simon, CH
Title presentation 2 Locally advanced HPV positive OPC: Selection of deintensification candidates and deintensification strategies
Speaker 2 Danny Rischin, AU
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 40’ Discussion
28
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Immunotherapy of cancer
Educational session Friday, 7 October 2016 – 10:15-11:45 90 mins
Topic Cancer Immunotherapy (CIT): What every oncologist should know
Chair Ignacio Melero, ES
Co-Chair Sjoerd van der Burg, NL
Title presentation 1 Back to the basics
Speaker 1 Sjoerd van der Burg, NL
Lecture/disc time 15’
Title presentation 2 Cancer vaccines: Can we make them work? (presentation to start with case)
Speaker 2 Kees Melief, NL
Lecture/disc time 25’
Title presentation 3 T cell therapy: For whom and when? (presentation to start with case)
Speaker 3 Inge Marie Svane, DK
Lecture/disc time 25’
Title presentation 4 Immune checkpoints: Do we really know how they work? (presentation to start with case)
Speaker 4 Ignacio Melero, ES
Lecture/disc time 25’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Topic Immunotherapy: The latest developments
Final Title Management of side effects
Speaker Georgina Long, AU
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
29
Special symposium Saturday, 8 October 2016 – 09:00-10:30 90 mins
Title symposium Whither immunotherapy?
Chair Ignacio Melero, ES
Co-Chair Mario Colombo, IT
Title presentation 1 Introduction
Speaker 1 Ignacio Melero, ES
Lecture time 1 5’
Title presentation 2 Tumour landscape: Clues for new targets
Speaker 2 Jerome Galon, FR
Lecture/disc time 2 20’
Title presentation 3 Converting a non-immunogenic into an immunogenic tumour
Speaker 3 Thomas Gajewski, US
Lecture/disc time 3 20’
Title presentation 4 Inflamed phenotype and immunotherapy: The H&N case
Speaker 4 Tanguy Seiwert, US
Lecture/disc time 4 20’
Title presentation 5 Combining immunotherapy: (ir)rational choices
Speaker 5 James Larkin, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Mario Colombo, IT
Lecture/disc time 6 5’
Multidisciplinary patient cases Sunday, 9 October 2016, 09:30-10:30
60mins
Topic Can immunotherapy be given safely to special subtypes of cancer patients?
Chair Paul Nathan, UK
Title presentation 1 Auto-immunity and cancer immunotherapy Bladder cancer patients treated with checkpoint inhibitors
Speaker 1 Paul Nathan, UK
Title presentation 2 Brain metastases and cancer immunotherapy Renal cell cancer patients treated with check point inhibitors
Speaker 2 Paolo Ascierto, IT
Title presentation 3 Chronic viral infections and cancer immunotherapy
Speaker 3 Emanuela Romano, FR
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
30
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Melanoma and other skin tumours
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Melanoma: Does the run of success continue?
Chair Dirk Schadendorf, DE
Co-Chair Paul Lorigan, UK
Title presentation 1 New checkpoints
Speaker 1 Jeffrey Weber, US
Lecture/disc time 30’
Title presentation 2 Neoantigens
Lecture/disc time 30’
Speaker 2 Dirk Schadendorf, DE
Title presentation 3 Novel immunotherapeutic constructs
Speaker 3 Speaker TBC
Lecture/disc time 30’
Challenge your Expert Sunday, 9 October 2016 – 08:00-09:00 60 mins
Final Title Will there be a place for adoptive T-cell therapy in the checkpoint inhibitors?
Speaker Jacob Schachter, IL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium Optimal combination and sequencing strategies in melanoma
Chair Reinhard Dummer, CH
Co-Chair Paolo Ascierto, IT
Title presentation 1 Introduction
Speaker 1 Reinhard Dummer, CH
Lecture time 1 5’
Title presentation 2 Rationale for combining
Speaker 2 Paolo Ascierto, IT
Lecture/disc time 2 20’
Title presentation 3 Rationale for sequencing
Speaker 3 Caroline Robert, FR
Lecture/disc time 3 20’
Title presentation 4 Can biomarkers help make the decision?
Speaker 4 Antoni Ribas, US
Lecture/disc time 4 20’
Title presentation 5 A closer look at the current guidelines on sequencing and combination (including new ESMO guidelines, how to move forward, clinical trial design)
Speaker 5 Paul Lorigan, UK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Paolo Ascierto, IT
Lecture/disc time 6 5’
31
Multidisciplinary patient cases Sunday, 9 October 2016 – 16:30-17:30 60 mins
Topic Continuum of management of stage IV in melanoma
Chair Olivier Michielin, CH
Title presentation 1 First-line
Speaker 1 Christian Blank, NL
Title presentation 2 Second-line
Speaker 2 Christoph Hoeller, AT
Title presentation 3 Brain metastasis
Speaker 3 Lars Bastholt, DK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
32
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
NETs and endocrine tumours
Educational session Monday, 10 October 2016 - 14:45-16:15 90 mins
Topic Management of advanced radioactive-iodine(RAI) refractory differentiated thyroid cancer (DTC)
Chair Martin Schlumberger, FR
Co-Chair Jaume Capdevila, ES
Title presentation 1 New insights in molecular biology of thyroid cancer
Speaker 1 Xavier Matias-Guiu, ES Lecture/disc time 30’
Title presentation 2 Enhancing iodine uptake in DTC
Speaker 2 Jaume Capdevila, ES
Lecture/disc time 30’
Title presentation 3 Treatment options in advanced RAI-refractory DTC
Speaker 3 Martin Schlumberger, FR
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 09:30-10:30 60 mins
Topic Adrenocortical tumours
Final Title What are genomics adding to patient management?
Speaker Jérôme Bertherat, FR
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Sunday, 9 October 2016 – 16:30-18:00 90 mins
Title symposium Precision medicine in NETs: Myth or reality?
Chair Rocio Garcia-Carbonero, ES
Co-Chair Kjell Öberg, SE
Title presentation 1 Introduction
Speaker 1 Rocio Garcia-Carbonero, ES
Lecture time 1 5’
Title presentation 2 Molecular tumour profiling and upcoming biomarkers: Will they help to deliver personalised medicine?
Speaker 2 Tim Meyer, UK
Lecture/disc time 2 15’
Title presentation 3 Minimally invasive surgery: Does it improve precision?
Speaker 3 Massimo Falconi, IT
Lecture/disc time 3 15’
Title presentation 4 Nuclear medicine: What do novel isotopes add to the treatment of NETs?
Speaker 4 Lisa Bodei, IT
Lecture/disc time 4 15’
Title presentation 5 Targeted drugs: Where are we now?
Speaker 5 Marianne Pavel, DE
Lecture/disc time 5 15’
Title presentation 6 Targeted drugs: Where are we heading to?
Speaker 6 Eric Raymond, CH
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Kjell Öberg, SE
Lecture/disc time 7 5’
33
Multidisciplinary patient cases Saturday, 8 October 2016 – 09:30-10:30 60 mins
Topic Pulmonary NETs
Chair James Yao, US
Title presentation 1 The grey zone in between intermediate and high grade NENs: A particular case
Speaker 1 Guido Rindi, IT
Title presentation 2 The minimal surgical approach for lung carcinoids: Pros and cons
Speaker 2 Manuel Garcia-Yuste, ES
Title presentation 3 The evolving landscape of systemic therapy for well differentiated neuroendocrine tumours of the lung
Speaker 3 James Yao, US
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
34
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Non-metastatic NSCLC and other thoracic malignancies
Educational session Friday, 7 October 2016 – 16:00-17:30 90 mins
Topic Optimal treatment of stage III NSCLC
Chair Johan Vansteenkiste, BE
Co-Chair Dirk de Ruysscher, NL
Title presentation 1 Which induction therapy for potentially resectable cases? (large volume to be included)
Speaker 1 Wilfried Eberhardt, DE
Lecture/disc time 30’
Title presentation 2 Which systemic therapy in concurrent chemoradiotherapy? (large volume to be included)
Speaker 2 Johan Vansteenkiste, BE
Lecture/disc time 30’
Title presentation 3 Which radiotherapy in concurrent chemoradiotherapy? (large volume to be included)
Speaker 3 Suresh Senan, NL
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Fragile patients with non-metastatic lung cancer: Facts and myths
Speaker Judith van Loon, NL
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 09:15-10:45 90 mins
Title symposium Lung cancer early detection and prevention
Chair Jesper Holst Pedersen, DK
Co-Chair Samuel Janes, UK
Title presentation 1 Introduction
Speaker 1 Samuel Janes, UK
Lecture time 1 5’
Title presentation 2 The NELSON trial
Speaker 2 Harry de Koning, NL
Lecture/disc time 2 20’
Title presentation 3 How to implement the NELSON trial
Speaker 3 Samuel Janes, UK
Lecture/disc time 3 20’
Title presentation 4 Defining risk populations with biomarkers
Speaker 4 Jesper Holst Pedersen, DK
Lecture/disc time 4 20’
Title presentation 5 Smoking cessation
Speaker 5 Haseem Ashraf, DK
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Jesper Holst Pedersen, DK
Lecture/disc time 6 5’
35
Multidisciplinary patient cases Sunday, 9 October 2016 – 09:30-10:30 60 mins
Topic How to approach a patient with oligometastatic NSCLC
Chair Merina Ahmed, UK
Title presentation 1 A simple case
Speaker 1 Merina Ahmed, UK
Title presentation 2 A difficult case
Speaker 2 Niels Reinmuth, DE
Title presentation 3 An impossible case
Speaker 3 Jens Benn Soerensen, DK
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
36
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
NSCLC, metastatic
Educational session 1 Monday, 10 October 2016 – 14:45-16:15 90 mins
Topic The earthquake of immunotherapy in lung cancer
Chair Luis Paz-Ares, ES
Co-Chair Solange Peters, CH
Title presentation 1 Current results of immunotherapy in thoracic oncology
Speaker 1 Luis Paz-Ares, ES
Lecture/disc time 25’
Title presentation 2 Can we select the right patient for immunotherapy in NSCLC? The clinician’s point of view
Speaker 2 Silvia Novello, IT
Lecture/disc time 20’
Title presentation 3 Can we select the right patient for immunotherapy in NSCLC? The pathologist’s point of view
Speaker 3 Ming Tsao, CA
Lecture/disc time 20’
Title presentation 4 Management of side effects of immunotherapy
Speaker 4 Martin Reck, DE
Lecture/disc time 25’
Educational session 2 Monday, 10 October 2016 – 16:30-18:00 90 mins
Topic Next generation small molecule inhibitors
Chair Tony S. K. Mok, HK, CN
Co-Chair TBC
Title presentation 1 Third generation EGFR TKI’s
Speaker 1 Tony S. K. Mok, HK, CN
Lecture/disc time 30’
Title presentation 2 Novel ALK inhibitors
Speaker 2 Solange Peters, CH
Lecture/disc time 30’
Title presentation 3 Novel targets in NSCLC and the compounds to combat them
Speaker 3 Greg Riely, US
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title Lights and shadows in targeting KRAS driven lung cancer
Speaker Påsi Janne, US
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
37
Special symposium Saturday, 8 October 2016 – 11:00-12:30 90 mins
Title symposium A molecular profile in NSCLC patients: How? When? Why?
Chair Fabrice Barlesi, FR
Co-Chair Fiona Blackhall, UK
Title presentation 1 Introduction
Speaker 1 Fiona Blackhall, UK
Lecture time 1 5’
Title presentation 2 Molecular profiling for precision lung cancer
Speaker 2 Roman Thomas, DE
Lecture/disc time 2 20’
Title presentation 3 Organisation: Local, regional and national
Speaker 3 Fabrice Barlesi, FR
Lecture/disc time 3 20’
Title presentation 4 Clinical application of serial molecular biomarker monitoring
Speaker 4 Stephen Finn, IE
Lecture/disc time 4 20’
Title presentation 5 Getting the right drug to the right patient based upon molecular profiling
Speaker 5 Jean-Charles Soria, FR
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Fabrice Barlesi, FR
Lecture/disc time 6 5’
Special session Monday, 10 October 2016 - 14:45-16:15 90 mins
Title symposium Liquid biopsies
Chair Peter Meldgaard, DK
Co-Chair Rafal Dziadziuszko, PL
Title presentation 1 Introduction
Speaker 1 Peter Meldgaard, DK or Rafal Dziadziuszko, PL
Lecture time 1 5’
Title presentation 2 Solid tumour, liquid biopsy: Can blood samples give us the answers?
Speaker 2 Dennis (Yuk-Ming) Lo, HK, CN
Lecture/disc time 2 25’
Title presentation 3 Tracking changes: monitoring evolution of disease through circulating free DNA
Speaker 3 Peter Meldgaard, DK
Lecture/disc time 3 25’
Title presentation 4 Blood-based tumour genomics: Technological advances
Speaker 4 Tom Wurdinger, NL
Lecture/disc time 4 25’
Title presentation 5 Conclusions and clinical perspectives
Speaker 5 Peter Meldgaard, DK or Rafal Dziadziuszko, PL
Lecture/disc time 5 10’
38
Multidisciplinary patient cases Saturday, 8 October 2016 – 16:30-17:30 60 mins
Topic Definition and management of oligoprogression during treatment with TKI inhibitors
Chair Egbert Smit NL
Title presentation 1 Practicalities and risks of biopsy
Speaker 1 Josephine Barry, IE
Title presentation 2 Optimal genome profiling for re-biopsy of TKI resistant tumour
Speaker 2 Keith Kerr, UK
Title presentation 3 The perspective of the oncologist
Speaker 3 Egbert Smit NL
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
39
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Public health and health economics
Educational session 1 Sunday, 9 October 2016 – 16:30-18:00 90 mins
Topic Bad luck or bad knowledge? Evidence-based cancer prevention approaches
Chair Jack Cuzick, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Where to give prevention advice
Speaker 1 Henrik Grönberg, SE
Lecture/disc time 30’
Title presentation 2 Proven interventions
Speaker 2 Silvia Franceschi, FR
Lecture/disc time 30’
Title presentation 3 Unproven interventions
Speaker 3 Gareth Evans, UK
Lecture/disc time 30’
Educational session 2 Monday, 10 October 2016 - 14:45-16:15 90 mins
Topic Straightforward options for earlier detection and treatment of challenging cancer types
Chair Harry de Koning, NL
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Review of all cancers
Speaker 1 Harry de Koning, NL
Lecture/disc time 30’
Title presentation 2 Ovarian cancer prevention: Are we finally there?
Speaker 2 Speaker TBC
Lecture/disc time 30’
Title presentation 3 Novel insights into Barrett's oesophagus
Speaker 3 Massimiliano di Pietro, UK
Lecture/disc time 30’
Challenge your Expert Monday, 10 October 2016 – 08:00-09:00 60 mins
Final Title The development of novel anticancer drugs: How to raise the bar in oncology
Speaker Alberto Sobrero, IT
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
40
Special symposium Monday, 10 October 2016 – 11:00-12:30 90 mins
Title symposium Streamlining the equitable delivery of anti-cancer drugs: Sharing common grounds for a pan-European vision of value
Chair Rosa Giuliani, IT
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Co-chair
Lecture time 1 5’
Title presentation 2 Equitable and affordable cancer care: Is Europe a union for real?
Speaker 2 Richard Sullivan, UK
Lecture/disc time 2 15’
Title presentation 3 How the European Commission's HTA initiative and the HTA network can promote consistent assessment of cancer care treatments in the EU
Speaker 3 Andrzej Rys, BE
Lecture/disc time 3 15’
Title presentation 4 The EMA’s initiatives to speed up access to valuable cancer drugs: Adaptive pathways and flexible approaches
Speaker 4 Francesco Pignatti, UK
Lecture/disc time 4 15’
Title presentation 5 Industry’s initiatives to reduce inequities and increase access to valuable cancer care: Myth or reality?
Speaker 5 Richard Bergstrom, US
Lecture/disc time 5 15’
Title presentation 6 ESMO’s initiatives to reduce disparities in cancer care: Promoting access to valuable drugs focusing on the magnitude of benefit
Speaker 6 Elisabeth de Vries, NL
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Rosa Giuliani, IT
Lecture/disc time 7 10’
41
ESMO Congress, Copenhagen 2016 NON ABSTRACT RELATED PROGRAMME
Sarcoma
Educational session Sunday, 9 October 2016 – 14:45-16:15 90 mins
Topic Desmoid tumours in 2016
Chair Dirk Strauss, UK
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Molecular pathology tools
Speaker 1 Frederic Chibon, FR
Lecture/disc time 30’
Title presentation 2 Local treatments
Speaker 2 Dirk Strauss, UK
Lecture/disc time 30’
Title presentation 3 Systemic treatments beyond chemotherapy and TKIs
Speaker 3 Bernd Kasper, DE
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 09:30-10:30 60 mins
Final Title Challenges in bone sarcoma
Speaker Stefan Bielack, DE
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
Special symposium Saturday, 8 October 2016 – 16:30-18:00 90 mins
Title symposium Personalising treatment for sarcoma
Chair Olivier Mir, FR
Co-Chair Not refunded role - TBD at a later stage
Title presentation 1 Introduction
Speaker 1 Co-chair
Lecture time 1 5’
Title presentation 2 Deep sequencing in sarcoma: The pathologist’s perspective
Speaker 2 Paolo dei Tos, IT
Lecture/disc time 2 15’
Title presentation 3 Treatment according to histological subtypes
Speaker 3 Silvia Stacchiotti, IT
Lecture/disc time 3 15’
Title presentation 4 Individualising radiation therapy (use / non-use)
Speaker 4 Rick Haas, NL
Lecture/disc time 4 15’
Title presentation 5 Molecular profiling for patients with STS
Speaker 5 Antoine Italiano, FR
Lecture/disc time 5 15’
Title presentation 6 Personalising treatment of bone sarcoma
Speaker 6 Enrique de Alava, ES
Lecture/disc time 6 15’
Title presentation 7 Conclusions and clinical perspectives
Speaker 7 Olivier Mir, FR Lecture/disc time 7 10’
42
Multidisciplinary patient cases Sunday, 9 October 2016 – 11:00-12:00 60 mins
Topic Systemic treatment for atypical GIST patients
Chair Winette van der Graaf, NL
Title presentation 1 Frail elderly
Speaker 1 Robin Jones, UK
Title presentation 2 Drug interactions
Speaker 2 Olivier Mir, FR
Title presentation 3 Local treatments in oligometastatic disease
Speaker 3 Alessandro Gronchi, IT
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
43
ESMO Congress, Copenhagen 2016
NON ABSTRACT RELATED PROGRAMME Supportive and palliative care
Educational session Sunday, 9 October 2016 – 16:30-18:00 90 mins
Topic Prophylaxis and treatment of symptoms in oncology
Chair Karin Jordan, DE
Co-Chair Fausto Roila, IT
Title presentation 1 Chemotherapy induced nausea and vomiting focusing on the updated MASCC/ESMO guidelines
Speaker 1 Karin Jordan, DE
Lecture/disc time 30’
Title presentation 2 Diagnosis and therapy of patients with febrile neutropenia
Speaker 2 Georg Maschmeyer, DE
Lecture/disc time 30’
Title presentation 3 Assessment and therapy of anxiety and depression
Speaker 3 Jon Håvard Loge, NO
Lecture/disc time 30’
Challenge your Expert Saturday, 8 October 2016 – 08:00-09:00 60 mins
Final Title Neurotoxicities assessment, prophylaxis and treatment
Chair Marie Fallon, UK
Speaker Maija Haanpää, FI
Lecture/disc time Presentation 30-40’ plus 30’-20’ Discussion
44
Special symposium Monday, 10 October 2016 – 09:15-10:45 90 mins
Title symposium Clinical challenges and patient needs based defined supportive and palliative interventions delivered by competent multidisciplinary professionals
Chair Florian Strasser, CH
Co-Chair Florian Scotté, FR
Title presentation 1 Introduction
Speaker 1 Florian Scotté, FR
Lecture time 1 5’
Title presentation 2 Integrated care pathways
Speaker 2 Stein Kaasa, NO
Lecture/disc time 2 20’
Title presentation 3 Evidence-based supportive care interventions
Speaker 3 Jørn Herrstedt, DK
Lecture/disc time 3 20’
Title presentation 4 Evidence-based palliative care interventions
Speaker 4 Florian Strasser, CH
Lecture/disc time 4 20’
Title presentation 5 Utilising the available multidisciplinary and interprofessional work force for optimal patient care
Speaker 5 Dorothy Keefe, AU
Lecture/disc time 5 20’
Title presentation 6 Conclusions and clinical perspectives
Speaker 6 Florian Scotté, FR and Florian Strasser, CH
Lecture/disc time 6 5’
Multidisciplinary patient cases Saturday, 8 October 2016 – 15:00-16:00 60 mins
Topic Pain from bone metastases
Co-Chairs (& spkrs) Daniele Santini, IT
Title presentation 1 The medical treatment of bone metastases
Speaker 1 Daniele Santini, IT
Title presentation 2 The role of radiotherapy in the control of bone pain
Speaker 2 Petra Feyer, DE
Title presentation 3 Analgesic multimodal management according to risk factors of cancer pain
Speaker 3 Eija Kalso, FI
Lecture/disc time Each speaker c. 10’ (incl. case presentation) plus c. 30’ Discussion
45
Special Session Friday, 7 October 2016 – 16:00-17:30 90 mins (1h30)
Title symposium
Early detection of cachexia, multimodal intervention and results
Co-Chair
Matti Aapro, CH
Co-Chair
Karin Jordan, DE
Title presentation 1
The role of nutritional support during radio-/chemotherapy
Speaker 1
Jann Arends, DE
Lecture time 1
20’
Title presentation 2
New drugs to treat patients with cancer anorexia cachexia syndrome
Speaker 2
Carla Ripamonti, IT
Lecture time 2
20’
Title presentation 3
The evidence of physical activity interventions during radio-/chemotherapy
Speaker 3
Matthew Maddocks, UK
Lecture time 3
20’
Title presentation 4
Elderly patients: Often malnourished
Speaker 4
Matti Aapro, CH
Lecture time 4
20’
Title presentation 5
General discussion: How to integrate cachexia management in routine cancer care
Speaker 5
All
Lecture time 5
10’
46
ESMO Congress, Copenhagen 2016 Congress Highlights
Congress Highlights Session 1 – The best of the ESMO 2016 Congress Tuesday, 11 October 2016 – 09:00-12:20 Chair part 1: Andrés Cervantes, ES Chair part 2: Fortunato Ciardiello, IT
09:00 20 Breast cancer, early stage Marco Colleoni, IT
09:20 20 Breast cancer, metastatic Robert E. Coleman, UK
09:40 20 Basic science and translational research Govindan Ramaswamy, US
10:00 20 CNS tumours Enrico Franceschi, IT
10:20 20 NETs and endocrine tumours Juan Valle, UK
10:40 20 Break
11:00 20 GU prostate Eleni Efstathiou, GR
11:20 20 GU non-prostate Andrea Necchi, IT
11:40 20 Non-metastatic NSCLC and other thoracic malignancies Dirk de Ruysscher, NL
12:00 20 NSCLC, metastatic Rafal Dziadzuszko, PL
12:20 20 Developmental therapeutics Christopher Twelves, UK
12:40 CLOSE
Congress Highlights Session 2 – The best of the ESMO 2016 Congress Tuesday, 11 October 2016 – 09:00-12:30 Chair part 1: Alberto Sobrero, IT Chair part 2: Josep Tabernero, ES
09:00 20 GI, colorectal Julien Taieb, FR
09:20 20 GI, non colorectal Arnaud Roth, CH
09:40 20 Sarcoma Sebastian Bauer, DE
10:00 20 Gynaecological cancers Cristiana Sessa, CH
10:20 20 Supportive and palliative care Florian Scotté, FR
10:40 20 Break
11:00 20 Head and neck cancer Amanda Psyrri, GR
11:20 20 Public health and health economics Rosa Giuliani, IT
11:40 20 Immunotherapy of cancer John Haanen, NL
12:00 20 Melanoma and other skin tumours Reinhard Dummer, CH
12:20 20 Haematological malignancies Steven Le Gouill, FR
12:40 CLOSE
47
ESMO Congress, Copenhagen 2016 ESMO YO sessions
YO Masterclass Sunday, 9 October 2016, 14:15-17:15 180’ (incl. 20’ coffee break)
Title session Harnessing the immune system for cancer therapy
Chair Matthias Preusser, AT
Co-chair Raffaele Califano, UK
Title presentation 1
Basic immunology for the medical oncologist
Speaker 1 Ignacio Melero, ES
Session Shooter 1 Leticia de Mattos-Arruda, ES
Lecture/discussion time
40’ (25’presentation plus 15’ discussion)
Title presentation 2
Immune checkpoint blockade and impact on clinical practice
Speaker 2 Michael Postow, US
Session Shooter 2 Jesus Corral, ES
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Coffee Break
20’
Title presentation 3
Combining immunotherapies with other anti-cancer therapies
Speaker 3 Paul Lorigan, UK
Session Shooter 3 Mila Petrova, BG
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Title presentation 4
Managing toxicities – case based discussions
Speaker 4 Jeffrey Weber, US
Session Shooter 4 Ramon de Mello, PT
Lecture/discussion time
40’ (25’ presentation plus 15’ discussion)
Vesalius Talk Sunday, 9 October 2016, 17:30-18:45 30 mins
Title session Developing an effective relationship between basic scientists and medical oncologists
Introduction Matthias Preusser, AT
Speakers Richard Marais, UK – EACR President Fortunato Ciardiello, IT – ESMO President Maria Sibilia, AT Marina Garassino, IT
Vesalius Cocktail – 45’ Follows on immediately after talk
48
YO Brunches YO Brunch 1 – 45’ Saturday 8 October, 11:00-12:00
Title EMA approval process for anticancer agents: What should the oncologist know?
Speaker Francesco Pignatti, UK
Session Coordinators
Raffaele Califano, UK Michiel Strijbos, BE
Lecture/disc time 45’
YO Brunch 2 – 45’ Sunday 9 October, 11:00-12:00
Title How to find the best literature for your paper: Pubmed and other academic databases
Speaker Elinor Harriss, UK
Session Coordinators
Jesus Corral, ES Mehmed Akif Ozturk, TR
Lecture/disc time 45’
YO Brunch 3 – 45’ Monday 10 October, 11:00-12:00
Title What makes a good review article? The Editors perspective
Lecture 1 Original articles
Speaker 1 Olivier Mir, FR
Lecture 2 Review
Speaker 2 Christoph Zielinski, AT
Session Coordinators
Sophie Postel-Vinay, FR Nikita Volkov, RU
Lecture/disc time 45’
49
YO Forum Monday 10 October, 16:00-17:30 90mins
Title
Professional development and communication skills
Chair Leticia de Mattos-Arruda, ES
Co-Chair Susana Banerjee, UK
Title presentation 1 Presentation skills and dealing with media
Speaker 1 Duncan Hart, UK
Session Shooter Mila Petrova, BG
Lecture time 1 45’ with questions / interactive part
Title presentation 2 How to become an effective leader and create a strong team
Speakers Evandro de Azambuja BE
Erika Martinelli, IT
Session Shooter Camilla Qvortrup, DK
Lecture time 2 45’ with questions
YO Fellowship session Monday, 10 October 2016, 14:15-15:45 90mins
Title ESMO Fellowships and awards
Chair Christoph Zielinski, AT
Co-Chair Matthias Preusser, AT
Title presentation 1 Introduction to session
Speaker 1 Christoph Zielinski, AT
Lecture time 1 5’
Title presentation 2 The ESMO Fellowship Programme
(Importance of YO for ESMO and how ESMO addresses the needs of
YOs through YOC and focus on different ESMO fellowships available)
Speaker 2 Valentina Guarneri, IT
Lecture time 2 15’
Title presentation 3 Practical tips from a former fellow
(from Translational Research / Clinical Research)
Speaker 3 Daniela Kolarevic, RS
Lecture time 3 15’
Title presentation 4 Best fellowship project 1
Speaker 4 Elena Castro, ES
Lecture time 4 15’
Title presentation 5 Best fellowship project 2
Speaker 5 Angela Lamarca, UK
Lecture time 5 15’
Title presentation 6 Conclusions
Speaker 6 Matthias Preusser, AT
Lecture time 6 5’
Awards: Presentation of the ESMO 2016 Fellows and 2015 Best Exam
Award 2015
20’
50
YO Mentorship session
Monday, 10 October 2016 – 09:30-10:30
60mins
Title ESMO Young Oncologists Mentorship session
Coordinators Michiel Strijbos, BE
Camilla Qvortrup, DK
Topic 1 x 2 tables Working in academia Practising quality onco
Table 1 Mentor
Table 2 Mentor
Roger Stupp, CH Enriqueta Felip, ES
Topic 2 x 2 tables Practicing oncologists
Table 3 Mentor
Table 4 Mentor
Sofia Braga, PT Stefan Rauh, LU
Topic 3 x 2 tables Industry as a career choice
Table 5 Mentor
Table 6 Mentor
Tom Lillie, UK Michelle Rashford, UK
51
ESMO Congress, Copenhagen 2016
Special Session
Sunday, 9 October 2016 – 11:00-12:30
Title symposium
Practising quality oncology across Europe and beyond: How can we
get there? Existing projects and future outlooks
Chair / Co-Chair
Stefan Rauh, LU
Co-Chair
Dirk Arnold, DE
Title presentation 1
Introduction
Speaker 1
Dirk Arnold, DE
Lecture time 1
5’
Title presentation 2
Quality improvement in centre structures. Experience within the German Cancer Society accreditation system
Speaker 2
Johannes Bruns, DE
Lecture time 2
10’
Title presentation 3
What is meant by "quality in oncology care"?
Speaker 3
Patrick Castel, FR
Lecture time 3
10’
Title presentation 4
Accreditation and Designation of Comprehensive Cancer Centres in Europe, the OECI's challenge
Speaker 4
Simon Oberst, UK
Lecture time 4
10’
Title presentation 5
Round table panel discussion
Speaker 5
ALL
Lecture time 5ii
35’
Speaker 5
Q&A
Lecture time 5ii
15’
Title presentation 6
Conclusions
Speaker 6
Stefan Rauh, LU
Lecture time 6
5’
52
ESMO Congress, Copenhagen 2016
Special Session
Friday, 7 October 2016 – 14:00-15:30
Title symposium Communication findings of clinical trials: The first 12 months from analysis
Chair / Co-Chair Matt Sydes, UK
Co-Chair Evandro de Azambuja, BE
Title presentation 1 Introduction
Speaker 1 Evandro de Azambuja, BE
Lecture time 1 5’
Title presentation 2 Disseminating results: What are we trying to achieve and who needs to hear?
Speaker 2 Annabelle South, UK
Lecture time 2 15’
Title presentation 3 What, when and how patients and the public want to know: New results and implications for practice
Speaker 3 Richard Stephens, UK
Lecture time 3 15’
Title presentation 4 The role of the press office and the role of the media
Speaker 4 Evandro de Azambuja, BE
Lecture time 4 15’
Title presentation 5 How clinical trial data leads to changes in practice: The perspective of the cost-effectiveness body
Speaker 5 Sarah Garner, UK
Lecture time 5 15’
Title presentation 6 Conclusions
Speaker 6 Matt Sydes, UK
Lecture time 6 10’
53
ESMO Congress, Copenhagen 2016
Special Session
Monday, 10 October 2016 – 11:00-12:30
Title symposium
Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Chair / Co-Chair Johann de Bono, UK
Co-Chair Roger Stupp, CH
Title presentation 1 Introduction
Speaker 1 Roger Stupp, CH
Lecture time 1 5’
Title presentation 2 Developing drugs targeting the PI3K/AKT signalling
Speaker 2 Li Yan, US
Lecture time 2 20’
Title presentation 3 Pembrolizumab: Rapidly moving the field forward through industry-academic collaborations
Speaker 3 Paul Haluska, US
Lecture time 3 20’
Title presentation 4 Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer
Speaker 4 Johann de Bono, UK
Lecture time 4 20’
Title presentation 5 The role of consortia and corporative groups in the modern era of cancer drug development
Speaker 5 Roger Stupp, CH
Lecture time 5 20’
Title presentation 6 Conclusions
Speaker 6 Johann de Bono, UK
Lecture time 6 5’
54
ESMO Congress, Copenhagen 2016
Special Session
Monday 10 October 2016, 11:00-12:30
Title symposium Reporting clinical trials: Faculty of principles of clinical trials and systemic therapy
Chair / Co-Chair Christian Dittrich, AT
Co-Chair Denis Lacombe, BE
Title presentation 1 Introduction
Speaker 1 Christian Dittrich, AT
Lecture time 1 5’
Title presentation 2 Improving the reporting of adverse events
Speaker 2 Bostjan Seruga, SI
Lecture time 2 15’
Title presentation 3 Unplanned versus pre-specified subgroup analysis reporting
Speaker 3 Douglas G. Altman, UK
Lecture time 3 15’
Title presentation 4 Quality of meta-analyses and why they sometimes lead to different conclusions
Speaker 4 Jean-Pierre Pignon, FR
Lecture time 4 15’
Title presentation 5 Early reporting of efficacy endpoints and its potential impact: Biostatistical part
Speaker 5 Jan Bogaerts, BE
Lecture time 5 15’
Title presentation 6 Early reporting of efficacy endpoints and its potential impact: Clinical part
Speaker 6 Fatima Cardoso, PT
Lecture time 6 15’
Title presentation 6 Conclusions
Speaker 6 Denis Lacombe, BE
Lecture time 6 5’
55
ESMO Congress, Copenhagen 2016
Special Session Sunday, 9 October 2016 – 14:45-16:15
Title symposium Clinical benefit of cancer drugs
Chair / Co-Chair
Elisabeth de Vries, NL
Co-Chair
Nathan Cherny, IL
Title presentation 1
Introduction
Speaker 1
Elisabeth de Vries, NL
Lecture time 1
5’
Title presentation 2
ESMO Magnitude of Clinical Benefit Scale (MCBS): version 1.1
Speaker 2
Nathan Cherny, IL
Lecture time 2
20’ including discussion
Title presentation 3
The different available approaches to qualify benefit of drugs in oncology
Speaker 3
Elisabeth de Vries, NL
Lecture time 3
20’ including discussion
Title presentation 4
Guidelines including grading of novel drugs with ESMO MCBS
Speaker 4
Andrés Cervantes, ES
Lecture time 4
20’ including discussion
Title presentation 5
Lecture to be defined
Speaker 5
Josep Tabernero, ES
Lecture time 5
20’ including discussion
Title presentation 6
Conclusions
Speaker 6
Elisabeth de Vries, NL
Lecture time 6
5’
56
ESMO Congress, Copenhagen 2016
Special Session
Saturday 8 October 2016 – 09:30-10:30
Session Title Practising Oncologists “How I treat” session Managing side effects and treatment related to advanced colorectal cancer
Chair & Speaker Dirk Arnold, PT
Title presentation 1 Introduction
Speaker 1 Stefan Rauh, LU
Lecture time 1 5’
Title presentation 2 Managing treatment side effects in advanced colorectal cancer
- When to stop oxaliplatine for toxicity - What side effects are prohibitive to continue oxaliplatine? - Diarrhoea management in gi treatment - GI chemotherapy in cirrhotic patients (FOLFOX, FOLFIRI,
etc; dose adaptations? limits?) - Fatigue /toxicity during regorafenib treatment - Patient selection: Who would not benefit ?
-
Speaker 2 Dirk Arnold, PT
Lecture time 2 20’
Title presentation 3 Discussion
Speaker 3 Dirk Arnod, PT and Stefan Rauh, LU
Lecture time 3 35’
57
ESMO Congress, Copenhagen 2016
Special Session Saturday 8 October 2016 – 15:00-16:00
Session Title Practising Oncologists “How I treat” session Managing issues in pancreatic cancer
Chair & Speaker Gábor Lakatos, HU
Pancreatic cancer: FOLFIRINOX in real life
- For which patient is it feasible? - Should FOLFIRINOX be used in the neoadjuvant or in the
palliative setting?
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
Pancreatic cancer: Optimizing neoadjuvant therapy in borderline resectable cases
- Which chemotherapy regimen to choose? - How many cycles are needed?
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
Borderline resectable pancreatic cancer
- Surgical aspects
5’ Speaker & case presentation: Gábor Lakatos, HU
5’ Discussant: Michel Ducreux, FR
10’ General Discussion
58
ESMO Congress, Copenhagen 2016
Special Session Sunday, 9th October 16:30 – 18:30 90 mins (1h30) Session plus 30 mins Award Section
Title symposium
ESMO Integrated Oncology & Palliative Care Community Session
Chair / Co-Chair
Florian Strasser, CH
Co-Chair
Anna-Marie Stevens, UK
Title presentation 1
Introduction
Speaker 1
Florian Strasser, CH
Lecture time 1
5’
Title presentation 2 The global ESMO Designated Centers of Integrated Oncology and Palliative Care Network: Characteristics, indicators, work force
Speaker 2
David Hui, US
Lecture time 2
20’
Title presentation 3
Building the community: Curricula, educational material, and opportunities to become a double-boarded oncologist and palliative care specialist
Speaker 3
Gudrun Kreye, AU
Lecture time 3
20’
Title presentation 4
Integration of psychosocial oncology care in routine oncology
Speaker 4 Luzia Travado, PT
Lecture time 4
20’
Title presentation 5
Selection of innovative practices of integrated oncology and palliative care performed in designated centers
Speaker 5
Richard Berman, UK
Lecture time 5
20’
Title presentation 6
Conclusions
Speaker 6 Anna-Marie Stevens, UK
Lecture time 6
5’
Award Section 30’ Designated Centre and Palliative Care Fellowship Awards
Presenter Nathan Cherny, IL and Florian Strasser, CH
Presenter Fellowship Awards, Gudrun Kreye, AU
59
ESMO Congress, Copenhagen 2016
Special Session
Sunday 9 October 2016 – 09:00-10:30
Title symposium
Women 4 Oncology
Chair / Co-Chair
Solange Peters, CH
Co-Chair
Sumitra Thongprasert, TH
Title presentation 1
Introduction and results of the 2016 W4O survey
Speaker 1
Solange Peters, CH
Lecture time 1
10’
Title presentation 2
The role of mentors and sponsorship in women’s careers
Speaker 2
Giuseppe Curigliano, IT
Lecture time 2
15’
Title presentation 3
What are the obstacles for female careers in oncology? Perspectives to help form the politics for political change
Speaker 3
Sandra Swain, US
Lecture time 3
15’
Title presentation 4
Imagine you were a woman: How would you plan and proceed with your career?
Speaker 4
Christoph Zielinski, AT
Lecture time 4
15’
Title presentation 5
Work–life balance: The need to develop policies to support flexibility
Speaker 5
Sonja Hammerschmid, AT
Lecture time 5
15’
Title presentation 8
W4O Award Presentation
Speaker 8
Christoph Zielinski, AT
Lecture time 8
2’
Title presentation 9
W4O Award Recipient (with PPT)
Speaker 9
Sumitra Thongprasert, TH
Lecture time 9
8’
Title presentation 10
Q&A and Closing remarks
Speaker 10
Solange Peters, CH
Lecture time 10’
10’
60
ESMO Congress, Copenhagen 2016
Special Session proposed by ESO
Friday, 8 October 2016, 16:00-17:30
Title symposium
Active Surveillance for low risk prostate cancer
Chair / Co-Chair
Riccardo Valdagni, IT
Co-Chair
Alan Horwich, UK
Title presentation 1
Why do we need Active Surveillance? The problem of overdiagnosis, indolent cancer and overtreatment
Speaker 1
Monique Roobol, NL
Lecture time 1
20’
Title presentation 2
What do we mean by Active Surveillance? Definition, criteria for inclusion and management, overview of protocols open for recruitment
Speaker 2
Chris Bangma, NL
Lecture time 2
20’
Title presentation 3
What do we need to improve the selection and management? Genetic profiling and serum markers
Speaker 3
Anders Bjartell, SE
Lecture time 3
10’
Title presentation 4
What do we need to improve the selection and management? MRI and targeted biopsy
Speaker 4
Caroline Moore, UK
Lecture time 4
10’
Title presentation 5
Living with an untreated cancer. The quality of life of men on Active Surveillance
Speaker 5
Lara Bellardita, IT
Lecture time 5
10’
Title presentation 6
Discussion
Speaker 6
All
Lecture time 6
20’